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Summary The relevance of electrical and mechanical dyssynchrony has been demonstrated in
heart failure with reduced ejection fraction. Preserved ejection fraction is present in as many as
50% of patients with chronic heart failure. Recent small studies suggest that both electrical and
mechanical left ventricular dyssynchrony are sometimes present in patients with heart failure
and preserved ejection fraction (HFPEF). These data remain controversial and a robust valida-
tion of this hypothesis has to be achieved. In the present paper, we review in detail the concepts
and try to justify the ongoing KaRen registry. This is a prospective, multicentre, international,
observational study to characterize the prevalence of electrical or mechanical dyssynchrony
in HFPEF and the resultant effect on prognosis. Patients are enrolled currently at the time
of an acute congestive episode. The diagnosis of HFPEF is made according to clinical data,
natriuretic peptides and echocardiography for the measurement of ejection fraction. Once sta-
bilized, patients return for a hospital check-up. They undergo clinical and biological evaluation,
electrocardiography and Doppler echocardiography. Thereafter, patients are followed every six
months, for at least 18months for mortality, and heart failure-related and non-cardiovascular
hospitalizations. KaRen aims to characterize electrical and mechanical dyssynchrony and to
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assess its prognostic impact in HFPEF. The results may improve our understanding of HFPEF and
generate answers to the question of whether or not dyssynchrony could be a target for cardiac
resynchronization therapy in HFPEF.
© 2010 Elsevier Masson SAS. All rights reserved.
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Résumé L’importance de l’asynchronisme électrique et mécanique a été largement démon-
trée chez les patients insufﬁsants cardiaques systoliques. L’insufﬁsance cardiaque à fraction
d’éjection préservée représente actuellement près de 50% de l’ensemble de la population
des insufﬁsants cardiaques. De récentes petites études ont suggéré qu’un certain degré
d’asynchronisme électrique et ou mécanique pouvait être observé chez les patients insuff-
isants cardiaques à fraction d’éjection préservée. Ces données restent controversées et une
large étude prospective restait ainsi nécessaire pour conﬁrmer ou non l’hypothèse d’un rôle de
l’asynchronisme dans la physiopathologie de cette maladie mal comprise qu’est l’insufﬁsance
cardiaque à fraction d’éjection préservée. C’est la raison pour laquelle, l’observatoire franco-
suédois KaRen a été initié. Celui-ci est donc prospectif, multicentrique et vise à décrire une
population d’insufﬁsants cardiaques à fraction d’éjection préservée en particulier, en termes
d’asynchronisme (électrique et mécanique) mais aussi en termes pronostique. Les patients sont
inclus lorsqu’ils sont vus pour un épisode congestif, puis sont réévalués quatre à huit semaines
plus tard en termes clinique, biologique, électro- et échochardiographique. Le diagnostic de
cette insufﬁsance cardiaque à fraction d’éjection préservée reste difﬁcile et dans KaRen, outre
la clinique et la fraction d’éjection, il a été ajouté un seuil de peptique natriurétique pour
retenir ou non le diagnostic. Ces patients sont revus à quatre à huit semaines après traite-
ment et suivis par téléphone tous les six mois, pendant 18mois. Nous allons ainsi étudier
prospectivement la prévalence et la signiﬁcation pronostique de l’asynchronisme, en parti-
culier échocardiographique et ce, en utilisant un protocole strict et des modalités d’analyse
actuelles. Nous devrions donc être en mesure, à partir du suivi prospectif de 400 patients, capa-
ble de mieux comprendre cette maladie et connaître l’importance de l’asynchronisme dans sa
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Abbreviations
CHF Congestive heart failure
CRT Cardiac resynchronization therapy
DHF Diastolic heart failure
EF Ejection fraction
HF Heart failure
HFPEF Heart failure with preserved ejection fraction
LV Left ventricular
SHF Systolic heart failure
Background
Electrical and mechanical dyssynchrony are common in
patients with HF and depressed (inferior to 40%) EF. How-
ever, as many as 50% of patients with chronic HF have
what is now called HFPEF. Patients with signs and symp-
toms of HFPEF (EF≥ 50%), but not those with restrictive,
DHF, will be studied in the KaRen multicentre study,
looking at prognosis and electrical and mechanical dyssyn-
chrony (using electrocardiography and echocardiography
performed according to a stringent protocol and reviewed
in a dedicated core laboratory) [1—9]. Recent small stud-
ies suggest that LV dyssynchrony might exist in patients with
HFPEF [10—14].
Electrical and mechanical dyssynchrony in HF with
depressed EF are known to be harmful [15,16], but we do
not have such information regarding HFPEF. Further studies
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re therefore necessary. But we also need to use a precise
eﬁnition of HFPEF, which is not merely a diagnosis made
n the basis of the presence of symptoms and preserved EF
17—19]. We need to ensure that the diagnosis (elevated
lling pressure) is in accordance with the guidelines [20]. In
ine with these principles, KaRen is an ongoing registry look-
ng at the prevalence and prognostic impact of dyssynchrony
n HFPEF [1].
We designed KaRen as a prospective, multicentre, inter-
ational, observational study to characterize HFPEF and
etermine whether electrical or mechanical dyssynchrony
ffects prognosis. We are looking at HF-related and non-
ardiovascular hospitalizations over a follow-up time of
8months.
lements of heart failure with preserved
jection fraction
HF affects about 2% of the western population, with preva-
ence increasing sharply from 1% in those aged 50 years to
0% in those aged over 75 years [4,7]. It is the most com-
on cause of hospitalization in patients aged over 65 years
4,21]. CHF is deﬁned as a syndrome characterized by an
mpaired ability of the heart to ﬁll with and/or eject blood,
esulting in a classical constellation of signs and symptoms
3].
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HFPEF is being recognized increasingly as a pathophysio-
ogical entity [4]. The proportion of patients with HFPEF is
bout 50% in studies of the general HF population [21—24].
hese patients were previously classiﬁed as having DHF or
FPEF. However, DHF has its own deﬁnition and may not be
trictly identical to HFPEF [4,5,23]. HFPEF can be deﬁned as
ollows:
an EF superior or equal to 45%, superior or equal to 50%,
or superior or equal to 55% [4];
the presence of clinical signs and symptoms of HF, accord-
ing to the Framingham criteria [25];
objective signs of congestion or elevated ﬁlling pressure
(natriuretic peptides, invasive haemodynamics, echocar-
diography) [20] in the absence of acute ischaemia, severe
valvular disease or other severe medical condition that
explains the congestion.
As the speciﬁcity of signs and symptoms of congestion
n elderly patients is debatable, the clinical evaluation is
eing corroborated systematically by the level of brain natri-
retic peptide or N-terminal prohormone brain natriuretic
eptide in the KaRen study [1]. Furthermore, echocardiog-
aphy should be performed before inclusion, which should
e able to verify the diagnosis [1].
The prognosis of HFPEF in epidemiological surveys is
early as poor as that of SHF, but in therapeutic clinical tri-
ls of HFPEF (PEP-CHF, CHARM-Preserved and I-PRESERVE),
he prognosis was much better than in clinical trials of
HF patients [18,19]. In I-PRESERVE, during a mean follow-
p of 49.5months, the primary outcome (death from
ny cause or hospitalization for a cardiovascular cause
HF, myocardial infarction, unstable angina, arrhythmia
r stroke]) occurred in 36.5% of patients [20]. Accord-
ng to a recent meta-analysis, mortality was 40.6% in the
educed LV EF group vs 32.1% in the HFPEF group after
n average follow-up of 47months [25]. The great dis-
repancy between registries and clinical trials might be
ue in part to the fact that patients were categorized
s HFPEF patients essentially on the basis of signs and
ymptoms of HF and a preserved EF; some ‘‘HF-like syn-
romes’’ might therefore have been included. We thus need
o consider objective criteria, to distinguish ‘‘true’’ HFPEF
rom ‘‘HFPEF-like syndromes’’, where comorbidities might
xplain symptoms that are not associated with any eleva-
ion in LV ﬁlling pressures. Furthermore, the clinical trials
xcluded older patients and/or those with signiﬁcant comor-
idities. In epidemiological surveys, information on cause
f death is not available and may well have been non-
ardiovascular.
Recently, Henkel et al. published complementary results.
hey found that HFPEF patients have less cardiovascular
isease before death and are less likely to experience
ardiovascular death than those with reduced EF, and
hat the proportion of cardiovascular deaths declined over
ime [26]. Such observations have also been reported by
ribouilloy et al. [7]. These recent data highlight the fact
hat the high mortality rates observed in HFPEF and SHF
ay have different causes. In SHF, the main reason is HF
pump dysfunction and sudden death), whereas in HFPEF,
he causes are mixed and are explained, at least in part,
y comorbidities [21,26—30]. Nevertheless, we have to
eep in mind that patients included in these studies may
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ot have actually had HFPEF. Indeed, in CHARMES, the
chocardiographic sub-study of the CHARM-Preserved study,
third of patients did not have any diastolic dysfunction
31]. In addition, in clinical practice, we have observed
hat the elderly patients in whom we diagnose HFPEF are
ospitalized repeatedly for congestion (that is cardiovas-
ular in origin most of the time) before dying. Under these
ircumstances, they need diuretics and blood pressure
ontrol [23,31]. Hence, we certainly have to improve
heir treatment to decrease their cardiovascular morbidity
30].
hy look for dyssynchrony in heart failure
ith preserved ejection fraction?
he prognostic importance of conduction disturbances (left
undle branch block) in the progression and severity of
HF has been established; this is not the case in HFPEF
16]. The prevalence of left bundle branch block is 25%
n SHF and 8.1 or 14% according to the I-PRESERVE and
HARM-Preserved studies, respectively [32]. Indeed, in the
HARM-Preserved population, left bundle branch block had
modest, or possibly no predictive impact on cardiovascu-
ar death or hospitalization for HF, after a mean follow-up of
8months [33]. In addition, no effect of left bundle branch
lock on prognosis was observed in the French epidemiology
tudy performed by Tribouilloy et al. [34].
According to Brutsaert, chronic HF might be seen as a
ingle, pathophysiological entity encompassing a continuous
pectrum of closely related phenotypes. Age, hypertension,
iabetes, being overweight and female have been associ-
ted with the HFPEF phenotype [35]. These characteristics
ave been shown to modify the process of LV remodelling
nd hypertrophy without preventing it. Also, haemodynamic
verload, neurohormonal imbalances, endothelial dysfunc-
ion, cytokines and even the mean collagen volume fraction
a measure of myocardial ﬁbrosis) have been reported to be
imilar in HFPEF and SHF [36,37]. It appears relevant, then,
o explore speciﬁcally the prevalence and consequence of
yssynchrony in patients who develop the HFPEF phenotype
4,33—37].
Recent studies on CRT indicate that early treatment
f dyssynchrony might be beneﬁcial [38]. The REVERSE
tudy (which included 610 SHF patients with New York
eart Association class I or II symptoms and a broad QRS
omplex) demonstrated signiﬁcant improvement in LV end-
ystolic volume in the group of patients treated with
RT (−18.4mL/m2 vs −1.3mL/m2; p < 0.0001), accompa-
ied by a reduced need for HF-related hospitalization in
he 262 European patients followed for 24months [38,39].
hese results were corroborated in the MADIT-CRT study,
esigned as a morbidity and mortality trial, which included
820 patients with New York Heart Association class I or II
ymptoms, LV EF inferior or equal to 30% and QRS superior
r equal to 130ms [40]. Also, non-randomized studies have
ielded limited but encouraging results in SHF with QRS infe-
ior to 120ms but with mechanical dyssynchrony [41,42].
he RethinQ trial did not conﬁrm the beneﬁcial effect of CRT
hen only mechanical dyssynchrony was found, according to
he criteria in that study [43,44].
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Table 1 Key exclusion criteria for patients in the KaRen
study.
1 Evidence of primary hypertrophic or restrictive
cardiomyopathy, or systemic illness known to be
associated with inﬁltrative heart disease
2 Known cause of right heart failure not related to
left ventricular dysfunction
3 Pericardial constriction
4 Clinically signiﬁcant pulmonary disease, as
evidenced by current requirement for home
oxygen
5 End-stage renal disease currently requiring dialysis
6 Bi-ventricular pacemaker (CRT); patients who have
a conventional pacemaker may be included
7 Anticipated or indication for cardiac surgery;
patients who have indication for surgery, but may
not undergo surgery because of some
contraindication (e.g. age), may NOT be included
8 Anticipated percutaneous intervention on aortic
stenosis; patients who undergo other percutaneous
intervention, for example PCI, may be included
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no correlation between systolic and diastolic dyssynchrony
[2,11,45,56].
KaRen was thus designed to study incidence and prog-
nostic impact of mechanical (systolic and diastolic) andCRT for heart failure patients with preserved ejection fracti
Mechanical dyssynchrony assessment
Ventricular dyssynchrony in SHF is frequent and portends
a worse outcome [45]. Electrical dyssynchrony, as indi-
cated by prolonged QRS duration (≥ 120ms) and/or left
bundle branch block, is present in approximately 30% of
patients [45]. In HFPEF, according to small monocentric
studies, the prevalence of electrical and/or mechanical
dyssynchrony during systole and/or diastole ranges from 10
to 60% [13,14,43—46]. With regard to the assessment of
mechanical dyssynchrony, despite a large number of mecha-
nistic and multicentre studies, only electrical dyssynchrony
in SHF is considered for treatment (QRS > 120ms, indication
for CRT) [47]. The assessment of mechanical dyssynchrony
remains non-consensual, operator-dependent but is also
dependent on haemodynamics or echocardiography. Nev-
ertheless, past studies and new imaging techniques are
providing new knowledge of the physiopathology of mechan-
ical dyssynchrony and new tools for its assessment. The
recently started Echo-CRT trial is also helping the aim of
characterizing mechanical dyssynchrony through a multicen-
tre study [48—51]. We therefore decided to evaluate the
prognostic signiﬁcance of QRS prolongation and mechanical
dyssynchrony variables in patients with HFPEF.
In the past ten years, many studies of mechanical dyssyn-
chrony and its assessment have been performed. QRS width
is correlated with prognosis, and concordant studies, even
in a narrow QRS population with LV EF inferior to 40%, have
demonstrated the prognostic value of interventricular and
intra-LV dyssynchrony [48].
As pointed out by Brutsaert and Sys many years ago,
ventricular relaxation and contraction are part of a con-
tinuous cycle, and HF with altered or preserved EF might
somehow be considered to be two expressions of the same
disease [52—54]. Thus, if dyssynchrony is now recognized as
a very important factor in SHF, the data that we have with
regard to HFPEF are sparse. De Sutter et al. found that,
in 60 patients with HF and an LV EF superior to 40%, the
prevalence of systolic intraventricular dyssynchrony mea-
sured by pulse tissue Doppler was 18% compared with 36%
in those with a low LV EF. However, in patients with HFPEF
and a QRS duration superior to 120ms, the prevalence of
intraventricular dyssynchrony in systole was the same in
both HF with depressed EF and in HFPEF [46]. Wang et al.,
studying 60HFPEF patients with tissue Doppler tools, found
that 58% had dyssynchrony in diastole (deﬁned as the onset
and not peak E’) and 33% in systole (considering the peak
S’) [13]. Another study with a very closed design showed
that in 92HFPEF patients, diastolic intra-LV dyssynchrony
was found in 56% of the population and systolic inter-LV
dyssynchrony in 33% of the population [55]. The prevalence
of mechanical dyssynchrony was quite high but less than
that observed in systolic CHF (57% in systole and 43% in
diastole). Twenty-ﬁve percent of the HFPEF patients had
isolated systolic dyssynchrony and the relationship between
systolic and diastolic dyssynchrony was poor.
Most patients with HFPEF have hypertension, but few
observational studies have focused on the prevalence of
mechanical dyssynchrony in hypertensive patients, com-
paring patients with diastolic dysfunction, high natriuretic
peptide levels or exercise limitations. The results appear
quite homogeneous. These studies used tissue Doppler imag-
F
tCRT: cardiac resynchronization therapy; PCI: percutaneous
coronary intervention.
ng to look for dyssynchrony and none of them followed the
atients to assess the impact of their ﬁndings on prognosis.
V dyssynchrony seems to be common among hypertensive
atients but particularly those with LV hypertrophy [2,56].
he severity of LV systolic dyssynchrony seems then to be
elated to the magnitude of LV hypertrophy. With regard
o diastolic dyssynchrony (assessed using the time to peak
’, by analogy to what is done for S’ using tissue Doppler
maging), the results are more confused, with no correlation
etween diastolic dyssynchrony and diastolic pattern, andigure 1. KaRen study design. CPX: cardiopulmonary exercise
esting.
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Nigure 2. Example of a KaRen patient with heart failure with pr
resent here an assessment of longitudinal dyssynchrony using two-
lectrical dyssynchrony in a characterized population of
FPEF. Patients will be examined by echocardiography after
reatment of the congestion (Table 1, Fig. 1). We will
ot focus only on the echocardiographic tools used in
ROSPECT and RethinQ to assess mechanical dyssynchrony
43,57]. We will use a multiparametric approach and new
reatment of the echocardiographic images, especially the
wo-dimensional speckle tracking strain analysis technique
roposed recently as being more reproducible and relevant
or measuring mechanical dyssynchrony in the longitudinal
irection but also in the radial or circumferential direc-
ions [58—62]. Our assessment of electrical and mechanical
yssynchrony will be centralized in core laboratories
echocardiography in Rennes, France and electrocardiogra-
hy in Stockholm, Sweden) and mechanical dyssynchrony
ill always be assessed using the same echocardiograph
achine and according to optimal stringency with regard
o the technique of image acquisition and analysis (Fig. 2).
urthermore, in a subset of patients (a predeﬁned sub-
tudy), we will assess mechanical dyssynchrony at the time
f congestion and afterwards, when the patient has been
reated optimally (and the overload controlled). KaRen
hould then be able to verify the existence of mechanical
yssynchrony in some patients diagnosed with HFPEF, but the
tudy will also provide an assessment of the robustness of
he diagnosis of HFPEF and whether associated mechanical
yssynchrony is inﬂuenced by load modiﬁcations [63].
onclusionhe KaRen study is being conducted to provide answers to
wo principal questions. What is the prevalence of electrical
nd/or mechanical dyssynchrony in the HFPEF population?
ow do electrical and mechanical dyssynchrony correlate
R
S
e
P
Ced ejection fraction and signiﬁcant mechanical dyssynchrony. We
nsional strain capabilities.
ith outcome as assessed by a combined endpoint of all-
ause death or HF hospitalization at 18-month follow-up?
his prospective, observational study also aims to assess the
otential usefulness of conducting clinical trials on CRT in
atients with HFPEF.
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